Seroepidemiology and evaluation of passive surveillance during 1988-1989 measles outbreak in Taiwan.
A seroepidemiological study was carried out to explore the risk factors of a measles outbreak that occurred among school children at a rural village (Li-Tse) in Taiwan. Among the 1166 participants, the percentage susceptible before the outbreak was 10.5% (122/1158) which was estimated as the sum of measles IgG-negative (29/1158) and IgM-positive (93/1166) individuals. Among 340 vaccinated children, 16 (4.7%) were measles IgM-positive and 10 (2.9%) were measles IgG-negative; therefore the vaccine failure rate was estimated to be 7.6% (26/340) and vaccine efficacy was 79.7% (95% confidence interval [CI] : 65.0-88.5). The most important risk factors for acquiring measles infection were the presence of other measles cases in the family (Odds Ratio [OR] = 32.5, P = 0.002) and the presence of more than two cases in a class (OR = 29.1, P = 0.003). The physician reporting rate was 6.1% (4/66), and the sensitivity of passive measles surveillance was only 4.3% (4/93) by active serosurvey. A concomitant rubella epidemic also amplified the inaccuracy of a passive reporting system based only on clinical diagnosis. Five children developed measles IgM but did not experience any symptoms, indicating that asymptomatic measles infection can occur. Our experience has highlighted three important areas for future measles elimination: (1) the need for serological evaluation of vaccinees, particularly those who were born during the introduction of mass immunization; (2) improvement in measles vaccine efficacy; and (3) further investigations on the role of asymptomatic transmission and susceptibles who remain after mass immunization.
Lee
M S
MS
Institute of Public Health, National Taiwan University (NTU), Taipei, Republic of China ROC.
King
C C
CC
Jean
J Y
JY
Kao
C L
CL
Wang
C C
CC
Ho
M S
MS
Chen
C J
CJ
Lee
G C
GC
D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis*; D002648:Child; D003430:Cross-Sectional Studies; D003906:Developing Countries; D004196:Disease Outbreaks; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D015994:Incidence; D008297:Male; D008457:Measles / Q000453:epidemiology* / Q000276:immunology; D008458:Measles Vaccine / Q000276:immunology; D008459:Measles virus / Q000276:immunology*; D011159:Population Surveillance; D012409:Rubella / Q000453:epidemiology / Q000276:immunology; D012411:Rubella Vaccine / Q000276:immunology; D013624:Taiwan
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008458:Measles Vaccine; D012411:Rubella Vaccine; C040901:rubella antibodies